MT Højgaard Holding A/S
On 23 November 2020, MT Højgaard Holding A/S announced that a share buy-back programme of an aggregated price of up to DKK 15,000,000 was launched with the purpose to meet obligations arising from the company’s share-based incentive programme.
The share buy-back programme is executed pursuant to the so-called "Safe Harbour" provisions in Regulation (EU) No. 596/2014 of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016. The programme will end no later than on 30 September 2021.
The following transactions have been executed from 8 March to 12 March 2021:
| Number of shares | Average purchase price (DKK) | Transaction value (DKK) | |
| Accumulated, last announcement | 38,820 | 169.93 | 6,256,646 |
| 8 March 2021 9 March 2021 10 March 2021 11 March 2021 12 March 2021 | 300 200 300 400 400 | 198.17 198.00 198.52 198.63 194.03 | 59,451 39,600 59,556 79,452 77,612 |
| Accumulated under the programme | 38,420 | 6,572,317 |
A detailed overview of transactions executed during the period 8 March to 12 March 2021 is attached to this announcement.
Following the above transactions, MT Højgaard Holding A/S owns a total of 38,420 treasury shares, corresponding to 0.493% of the company’s total share capital.
Contact: CFO Martin Stig Solberg may be contacted by phone on +45 2270 9365
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ALK Abello19.12.2025 22:46:46 CET | Press release
Major shareholder announcement
ALK Abello19.12.2025 22:46:46 CET | Pressemeddelelse
Storaktionærmeddelelse
Zealand Pharma19.12.2025 22:00:00 CET | Press release
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Boehringer Ingelheim Limited19.12.2025 21:10:00 CET | Press release
U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
Novartis Pharma AG19.12.2025 20:30:06 CET | Press release
Novartis and US government reach agreement on lowering drug prices in the US
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
